GW-501516 GlaxoSmithKline/Ligand.
GlaxoSmithKline and Ligand are developing GW-501516, a peroxisome proliferator-activator receptor-delta agonist for the potential treatment of dyslipidemia. Phase II clinical trials of this compound are ongoing.
Pelton
Patricia
P
Johnson & Johnson Pharmaceutical Research and Development, LLC, 1000 Route 202, Raritan, NJ 08869, USA. PPelton@prdus.jnj.com
D000818:Animals; D005227:Fatty Acids / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008253:Macaca mulatta; D051379:Mice; D008820:Mice, Obese; D047494:PPAR delta / Q000187:drug effects / Q000502:physiology; D013329:Structure-Activity Relationship; D013844:Thiazoles / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use
D005227:Fatty Acids; C425931:GW 501516; D000960:Hypolipidemic Agents; D047494:PPAR delta; D013844:Thiazoles; D005947:Glucose